Industry

CAMBRIDGE, Mass. & BEIJING & BASEL, Switzerland–(BUSINESS WIRE)–BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced that Julia Wang, Chief Financial Officer, and Angus Grant, Ph.D., Chief Business Executive, will participate in a fireside … [Read more…]

NEW YORK–(BUSINESS WIRE)–White Oak Healthcare Finance, LLC (“White Oak”) today announced it acted as sole lender and administrative agent of a senior credit facility to California Specialty Pharmacy (“CSP” or the “Company”) to support the acquisition by Assured Healthcare Partners (“AHP”). CSP is a specialty infusion pharmacy platform focused on managed care. “Specialty drugs require … [Read more…]

State-of-the-art facility in Austin, Texas, enhances early phase research opportunities through new equipment and expertise, positioning CRO for further growth RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–#Austin—Worldwide Clinical Trials, Inc. (Worldwide), the industry’s leading global, midsize, full-service contract research organization (CRO), has announced that it expanded its early phase clinical trial capabilities by opening its Bioanalytical Center … [Read more…]

New service available through LifeWorks iCBT TORONTO–(BUSINESS WIRE)–LifeWorks, a global leader in digital and in-person wellbeing solutions, today launched a new internet-based cognitive behavioural therapy (iCBT) program for healthcare workers dealing with burnout. This specialized program is available in Canada and the United States through LifeWorks iCBT, the company’s digital mental health platform. The program … [Read more…]

AI-powered pathology leader announces novel continuous scoring system for fibrosis that may be accurate and predictive of patient progression as company doubles down on commitment to changing the standard of care for fibrosis treatment BOSTON–(BUSINESS WIRE)–#NASH—PathAI, a global leader in AI-powered pathology, today announced it will present three presentations at this year’s International Liver Congress … [Read more…]

2022 Promega Corporate Responsibility Report shows investments in solar arrays led to ten-fold increase in renewable energy usage in last three years MADISON, Wis.–(BUSINESS WIRE)–#sustainability–Promega Corporation now draws over 20% of its global electricity from renewable sources. The 2022 Promega Corporate Responsibility Report, released today, details how the biotechnology company’s investments in solar arrays have … [Read more…]

Reproxalap Statistically Superior to Vehicle for Both Prespecified Primary Endpoints of Schirmer Test (p=0.0001) and ≥10 mm Schirmer Test Responder Proportions (p<0.0001) TRANQUILITY-2 Results May Allow for the Most Comprehensive Dry Eye Disease New Drug Application (NDA) Submission to Date Pending Pre-NDA Meeting with the U.S. Food and Drug Administration (FDA), Clinical Efficacy Trials of … [Read more…]

NATICK, Mass.–(BUSINESS WIRE)–Pillar Biosciences, the leader in Decision Medicine™, which develops and distributes next-generation sequencing (NGS) tests to localize testing and reduce time to treatment initiation and overall testing costs, today announced the appointment of Vincent Ricci as Chief Financial Officer. Mr. Ricci will lead Pillar Biosciences’ finance and investor relations functions as the company … [Read more…]

Ms. Gambale’s experience in data technology and finance supports Avellino’s bioinformatics precision medicine mission MENLO PARK, Calif.–(BUSINESS WIRE)–#avagen—Avellino Lab USA, Inc. (Avellino), a global leader in molecular diagnostics, is pleased to announce the appointment of Virginia Gambale to its Board of Directors. Ms. Gambale is currently Managing Partner of Azimuth Partners LLC, which is focused … [Read more…]

WATERTOWN, Mass.–(BUSINESS WIRE)–Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that data from Enanta’s internal development program portfolio for hepatitis B virus (HBV) and its out-licensing program portfolio for non-alcoholic steatohepatitis (NASH) have been accepted for poster presentations at the European … [Read more…]